# Taysha Gene Therapies Inc. (TSHA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $5.60, market value $1.8 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Taysha Gene Therapies Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 332.7×**. Each dollar of revenue is priced at 332.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 7.6×**. The shares trade at 7.6× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -7.3%** (5-yr avg -40.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -44.1%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 532.5%**. Return on all capital, debt included, is 532.5%: comfortably above what that capital costs.
- **Return on assets: -43.6%**. Each dollar of assets produces -43.6% of profit.

## Growth
- **Revenue growth (1 yr): 17.3%** (3-yr 57.5%/yr). Revenue grew 17.3% over the last year.
- **EPS growth (1 yr): 5.6%**. Earnings per share rose 5.6%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.20**. Debt is 0.20 times equity: a conservative balance sheet.
- **Altman Z-score: 11.33**. A Z-score of 11.33 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Taysha Gene Therapies Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Taysha Gene Therapies Inc.; the consensus is strong_buy, with an average price target of $13.33 (+138% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 71.8%** (YTD 1.8%, 3-mo 1.8%). The shares are up 71.8% over twelve months including dividends.
- **From 52-week high: -23.3%** (106.6% above the low). Trading 23% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 41**. An RSI of 41 is neutral.
- **Beta (1 yr): 1.84** (volatility 90%). Beta of 1.84 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=TSHA · Page: https://foliofundamentals.com/stocks/tsha

Not investment advice.